Multicenter phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma
Phase 2
- Conditions
- oral squamous cell carcinoma
- Registration Number
- JPRN-C000000023
- Lead Sponsor
- Chubu research group on oral cancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they had active infections, active second malignancy, severe heart diseases, interstitial pneumonia or lung fibrosis, severe pleural effusion or pericardial effusion that required drainage, fever more than or equal to 38 C, symptomatic brain metastasis, severe psychological disease, and possible pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical and histopathological effect of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma
- Secondary Outcome Measures
Name Time Method Safety of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie docetaxel and nedaplatin synergy in oral squamous cell carcinoma?
How does neoadjuvant docetaxel/ nedaplatin compare to standard-of-care chemoradiotherapy for T3-T4 oral SCC?
Which biomarkers correlate with pathological response to docetaxel- nedaplatin neoadjuvant regimen in oral squamous cell carcinoma?
What are the most common adverse events associated with docetaxel and nedaplatin combination in head and neck cancers?
Are there alternative platinum-based combinations to nedaplatin for improving resectability in locally advanced oral SCC?